SOLIGENIX, INC. 8-K

What Happened
Soligenix, Inc. (SNGX) filed a Current Report on Form 8-K on February 12, 2026 to announce a shareholder update letter from President and CEO Dr. Christopher J. Schaber. The letter, released via a company press release (filed as Exhibit 99.1), summarizes recent corporate progress, clinical developments across Soligenix’s pipeline, upcoming milestones, and the company’s financing strategies and cash runway.

Key Details

• Filing date: February 12, 2026; press release/shareholder letter is filed as Exhibit 99.1 to the 8-K.
• Author: Christopher J. Schaber, Ph.D., President and Chief Executive Officer (signed the filing).
• Topics covered: corporate progress, clinical program updates, upcoming milestones, financing approaches and cash runway guidance.
• The filing includes the company’s Safe Harbor statement noting that forward-looking statements are subject to risks and uncertainties.

Why It Matters
This 8-K gives investors a direct update from Soligenix’s CEO on the company’s clinical and corporate status and on how management is thinking about funding and runway—information useful for assessing near-term operational prospects and potential financing/dilution needs. The Safe Harbor language reminds investors that forward-looking comments are subject to change based on risks described in Soligenix’s SEC filings. For specific financial figures or definitive milestones, investors should review the full press release (Exhibit 99.1) and the company’s other SEC reports.